Guardant Health, Inc.
Guardant Health provides blood and tissue tests that analyze cancer-related genetic and epigenomic changes to help oncologists select treatments, detect residual disease in early-stage cancer patients, and screen for cancer in asymptomatic individuals.
Guardant Health, Inc is a Healthcare company operating in Diagnostics & Research with a $17.08B market cap.
GH beat consensus EPS by 0.0% in Q1 FY2026, reported May 7, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks GH's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 6/10 quarters with 60% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GH.
$ curl https://api.spokenalpha.com/v1/companies/GHFAQ
Spoken Alpha indexes GH's earnings call transcripts at https://spokenalpha.com/companies/GH. Each call links to attributed speakers and parsed analyst Q&A. Guardant Health, Inc.'s own investor relations page is at https://investors.guardanthealth.com/overview/default.aspx.
Guardant Health, Inc. (GH) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
Guardant Health, Inc. (GH) operates in the Healthcare sector (Diagnostics & Research industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-07 | $-0.45 | $-0.47 | +5.0% | $301.7M | — | — | EODHD |
| Q4 FY2025 | 2026-02-18 | $-0.50 | $-0.78 | +35.5% | $281.3M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $-0.39 | $-0.79 | +50.6% | $265.2M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $-0.44 | $-0.72 | +38.9% | $232.1M | — | — | EODHD |
| Q1 FY2025 | 2025-06-11 | $-0.49 | $-0.85 | +42.4% | $203.5M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $-0.62 | $-0.50 | -23.1% | $201.8M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.88 | $-0.74 | -18.9% | $191.5M | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.84 | $-0.74 | -13.5% | $177.2M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.94 | $-0.85 | -10.6% | $168.5M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $-0.85 | $-0.86 | +1.2% | $155.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-05 | $-0.73 | $-0.95 | +23.2% | $143.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.67 | $-1.18 | +43.2% | $137.2M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-1.30 | $-1.32 | +1.5% | $128.7M | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-1.36 | $-1.37 | +0.7% | $126.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-1.41 | $-1.26 | -11.9% | $117.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-1.27 | $-1.21 | -5.0% | $109.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-1.21 | $-1.21 | 0.0% | $96.1M | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $-0.89 | $-1.15 | +22.6% | $108.1M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-1.06 | $-0.97 | -9.3% | $94.8M | — | — | EODHD |
| Q2 FY2021 | 2021-08-04 | $-0.96 | $-0.85 | -12.9% | $92.1M | — | — | EODHD |
Source: EODHD. GH reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.17 | $4.35 | -4.2% | -2.1% | -5.1% |
| Q4 FY2026 | $4.55 | $4.54 | +0.2% | +6.6% | +9.3% |
| Q3 FY2026 | $4.14 | $4.28 | -3.2% | +5.5% | +2.8% |
| Q2 FY2026 | $4.55 | $4.39 | +3.6% | +4.0% | +1.8% |
| Q1 FY2025 | $4.97 | $4.55 | +9.3% | +3.9% | +4.7% |
CEO since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
| Q4 FY2025 |
| $4.85 |
| $4.62 |
| +4.9% |
| +1.5% |
| -1.0% |
| Q3 FY2025 | $4.51 | $4.58 | -1.5% | 0.0% | -0.6% |
| Q2 FY2025 | $4.64 | $4.63 | +0.2% | +9.0% | +12.0% |
| Q1 FY2024 | $4.58 | $4.62 | -0.9% | -0.2% | +0.9% |
| Q4 FY2024 | $4.63 | $4.45 | +4.1% | -2.1% | -3.3% |